Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2020-09-04 AGM Information
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
200903 PR AGM EGM 4 Sept 2020 invitation ENG_FINAL.pdf
AGM Information Classification · 98% confidence The document is explicitly titled 'Invitation to the Extraordinary Shareholders' Meeting' and details the date, time, location, and procedures for shareholders to participate in this meeting. This directly relates to the governance and scheduling of a shareholder meeting, which falls under the scope of AGM/Shareholder Meeting materials. Since it is an 'Extraordinary' meeting, and the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', this is the most appropriate classification, as EGMs (Extraordinary General Meetings) are functionally similar to AGMs in terms of required documentation and purpose (shareholder voting/information). It is an invitation/notice for the meeting, not the voting results (DVA) or a proxy solicitation document (PSI), but rather the core announcement of the meeting itself.
2020-09-04 English
200903 PR AGM EGM 4 Sept 2020 invitation NL_FINAL.pdf
AGM Information Classification · 97% confidence The document is titled "Oproeping tot de Buitengewone Algemene Aandeelhoudersvergadering" (Call for the Extraordinary General Shareholders' Meeting) and is dated September 4, 2020, calling for a meeting on September 25, 2020. This document is an official invitation and notice regarding a shareholders' meeting, specifically an Extraordinary General Meeting (EGM), which is a type of general meeting. While it relates to a meeting, it is the formal notice/call itself, not the voting results (DVA) or the presentation materials (AGM-R). In the context of corporate filings, a formal notice or call for a general meeting, especially when it details procedures for voting by proxy or letter due to external circumstances (like COVID-19), often falls under the scope of materials related to shareholder meetings. Given the options, this is most closely related to the materials distributed to shareholders for a meeting, which often overlaps with Proxy Solicitation & Information Statement (PSI) or, if it were the final results, DVA. However, since it is the *call* for the meeting, and it is not a standard 10-K, ER, or IR, it is a specific type of corporate action announcement. Since the document is a formal 'Oproeping' (Call/Notice) for a General Shareholders' Meeting, it is highly relevant to the materials sent to solicit participation and votes, making 'PSI' (Proxy Solicitation & Information Statement) a strong candidate, as these documents contain the notice and voting instructions. Alternatively, if the meeting was the AGM, AGM-R would apply, but this is an EGM. Given the content is the formal notice and instructions for participation/voting at a general meeting, PSI is the most appropriate fit among the specific options, as it covers the solicitation of votes and provision of information for meetings.
2020-09-04 Dutch
200902 Biocartis H1 2020 Financial Report ENG_FINAL_OK.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2020 (H1 2020), containing a CEO message, business review, and references to condensed consolidated interim financial statements. It covers a period shorter than a full fiscal year and provides substantive financial and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2020
2020-09-03 English
200902 Biocartis H1 2020 Financial Report NL_FINAL_OK.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first six months (H1) of 2020, as indicated by the title 'Activiteitenoverzicht H1 2020' and the inclusion of 'Verkorte geconsolideerde tussentijdse financiële informatie' (condensed consolidated interim financial information). It contains detailed management commentary, operational highlights, and financial data for the interim period. It is not a mere announcement (RPA) or a standalone audit report, but a full interim report. H1 2020
2020-09-03 Dutch
200902 Biocartis H1 2020 Financial Report ENG_FINAL.pdf
Management Reports Classification · 99% confidence The document text contains a table of contents that explicitly lists sections such as 'Message from the CEO', 'Responsibility statement', 'Business review of the first half of 2020', and most critically, 'Condensed consolidated interim financial statements for the period ended 30 June 2020'. The content discusses performance for the 'first six months of 2020' and includes condensed consolidated financial statements for the period ended June 30, 2020. This structure and content strongly indicate a comprehensive financial report covering a period shorter than a full year (H1 2020). This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K) because it covers only six months, and it is the report itself, not just an announcement of the report (RPA/RNS).
2020-09-03 English
200902 Biocartis H1 2020 Financial Report NL_FINAL.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2020, as indicated by the title 'Activiteitenoverzicht H1 2020' and the inclusion of 'Verkorte geconsolideerde tussentijdse financiële informatie' (Condensed consolidated interim financial information). It contains detailed management commentary, operational highlights, and financial data for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report. H1 2020
2020-09-03 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.